Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| GHK-Cu | Thymosin Alpha-1 | |
|---|---|---|
| Category | Growth Factors | Growth Factors |
| Standard Dose | Research indicates 1-2 mg daily via subcutaneous injection, or topical application at 1-3% concentration in cream/serum. | Research indicates 1.6 mg administered twice weekly via subcutaneous injection. |
| Timing | Evening administration preferred for skin rejuvenation (aligns with nocturnal repair cycles). Topical can be applied morning and evening. | Morning administration preferred. No food timing restrictions. |
| Cycle Duration | 8-12 weeks for injectable cycles. Topical use can be ongoing. | 8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance. |
| Evidence Level | moderate_human | strong_human |
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) that modulates gene expression affecting 31.2% of human genes. It activates Wnt/beta-catenin signaling for hair follicle growth, stimulates TGF-beta pathway for tissue remodeling, and promotes collagen and glycosaminoglycan synthesis while modulating metalloproteinase activity. The copper ion serves as a cofactor for enzymes essential to wound healing including superoxide dismutase and lysyl oxidase.
Research indicates 1-2 mg daily via subcutaneous injection, or topical application at 1-3% concentration in cream/serum.
Evening administration preferred for skin rejuvenation (aligns with nocturnal repair cycles). Topical can be applied morning and evening.
8-12 weeks for injectable cycles. Topical use can be ongoing.
Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus that acts as a pleiotropic immune modulator through Toll-like receptors (TLR2, TLR3, TLR4, TLR7, TLR9) on myeloid and plasmacytoid dendritic cells. It activates downstream IRF3, NF-kB, p38MAPK, and MyD88 signaling pathways to promote cytokine production. It modulates TNF-alpha, IFN-gamma, and IL-2 in CD4+ and CD8+ T lymphocytes by upregulating CD40/CD40L and downregulating PD-L1/PD-1 expression, enhancing both innate and adaptive immunity.
Research indicates 1.6 mg administered twice weekly via subcutaneous injection.
Morning administration preferred. No food timing restrictions.
8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →